Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MI Paste® ONE Perio (GC MI Paste One Perio) is a two-in-one anti-gingivitis toothpaste and remineralizing paste developed and marketed by GC America Inc.. It combines the functions of an anti-gingivitis dentifrice and MI Paste Plus®. The formulation contains stannous fluoride (0.454% w/w) as its active drug ingredient and RECALDENT® (CPP-ACP — Casein Phosphopeptide-Amorphous Calcium Phosphate), a milk-derived protein complex, as a functional remineralizing component. Stannous fluoride provides long-lasting anti-biofilm efficacy to prevent and treat gingivitis, as well as anticaries action, while RECALDENT® delivers bioavailable calcium and phosphate to promote tooth remineralization, rebuild enamel, and relieve sensitivity. It is indicated for the prevention and treatment of gingivitis, dental caries prevention, tooth sensitivity, and white spot lesion prevention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MI Paste ONE Perio.